Literature DB >> 27704600

Reply to 'Endpoints in strategies to reduce polypharmacy'.

Tim Johansson1, Maria Flamm1, Andreas Sönnichsen2.   

Abstract

Mesh:

Year:  2016        PMID: 27704600      PMCID: PMC5237688          DOI: 10.1111/bcp.13125

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  3 in total

1.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

Review 2.  Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis.

Authors:  Tim Johansson; Muna E Abuzahra; Sophie Keller; Eva Mann; Barbara Faller; Christina Sommerauer; Jennifer Höck; Christin Löffler; Anna Köchling; Jochen Schuler; Maria Flamm; Andreas Sönnichsen
Journal:  Br J Clin Pharmacol       Date:  2016-05-07       Impact factor: 4.335

3.  Endpoints in strategies to reduce polypharmacy.

Authors:  Andrés Gaviria-Mendoza; Jorge Enrique Machado-Alba; Juan Pablo Castaño-Montoya; Manuel Enrique Machado-Duque; Claudia Giraldo-Giraldo
Journal:  Br J Clin Pharmacol       Date:  2016-09-29       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.